XML 19 R33.htm IDEA: XBRL DOCUMENT

16. Segment Information (Tables)

3 Months Ended

Mar. 31, 2014

A summary of results by segments is as follows:

	Three Months Ended March 31, 2014 ($000											Three Months Ended March 31, 2013 ($000)
	Bio-			ProElite								Bio-		ProElite
	Pharma			(Discont.)		Other			Total			Pharma		(Discont.)			Other			Total
Revenues	$	–		$	–	$	–		$	–		$	–	$	–		$	–		$	–
Cost of sales		–			–		–			–			–		–			–			–
Gross margin		–			–		–			–			–		–			–			–
Deprec. & Amort		1			–		477			478			–		–			9			9
Segment profit		(1	)		–		(477	)		(478	)		–		–			(9	)		(9	)
Operating expenses		183			–		710			893			–		–			2,084			2,084
Other (income)/expenses		–			–		5			5			–		–			20			20
Impact of derivative securities		–			–		–			–			–		–			237			237
Net loss from continuing ops.		(184	)		–		(1,192	)		(1,376	)		–		–			(2,350	)		(2,350	)
Loss from discontinued ops.		–			–		–			–			–		(127	)		–			(127	)
Preferred dividends		–			–		–			–			–		–			124			124
Net loss attributable to common shareholders	$	(184	)	$	–	$	(1,192	)	$	(1,376	)	$	–	$	(127	)	$	(2,474	)	$	(2,601	)

Assets at End of Period	$	230		$	344	$	25,878		$	26,452		$	–	$	1,677		$	511		$	2,188
Liabilities at End of Period	$	2,779		$	625	$	7,291		$	10,695		$	–	$	1,998		$	19,927		$	21,925

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details